Addressing Anti-VEGF Durability Issues Through Novel Surgical Approaches for the Treatment of nAMD and DME

Author(s)/Faculty: Carl D. Regillo, MD, FACS; Margaret A. Chang, MD, MS; Dilsher S. Dhoot, MD
Release Date: 2/17/2022Expiration Date: 2/16/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
Intravitreal anti–vascular endothelial growth factor (VEGF) therapy has revolutionized the management paradigm for patients with retinal vascular diseases, yet there is still an unmet need to address treatment burden and loss of patient adherence due to dosing schedules. For patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), there is ongoing evaluation of gene therapy and surgical delivery devices with the potential to extend treatment intervals while maintaining visual acuity. These advances in treatment delivery require unique surgical approaches for optimal efficacy outcomes and safety. In this CME activity, experts in the field review the data on the recently approved port delivery system and emerging gene therapy approaches for managing nAMD and DME. Faculty will evaluate novel surgical techniques and review clinical cases illustrating best practices for reducing potential surgical complications.